Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2013: Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART

The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for highly treatment-experienced people with resistance to 2 or more antiretroviral drug classes, researchers reported in a poster presented at the20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.

alt

Read more:

CROI 2013: New Antiretroviral Agents: Cenicriviroc [VIDEO]

Tobira's cenicriviroc, a dual CCR5 and CCR2 receptor blocker with both antiviral and anti-inflammatory action, appears effective and better tolerated than some currently approved drugs, according to data presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

CROI 2013: HIV Treatment for Children Safe and Highly Effective without Laboratory Monitoring

Children did just as well on antiretroviral therapy (ART) without routine laboratory monitoring of CD4 cell counts or drug side effects as those who received regular monitoring during 4 years of follow-up, researchers from Uganda and Zimbabwe reported at March 6 the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

CROI 2013: New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated

Tenofovir alafenamide fumarate, or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harboring HIV more easily than the older disoproxil fumarate (TDF), allowing for similar antiviral efficacy with smaller doses and with less adverse effect on kidneys and bones,researchers reported Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

CROI 2013: New Tenofovir Alafenamide Looks Easier on Kidneys [VIDEO]

A new pro-drug formulation of the widely used nucleotide reverse transcriptase inhibitor analog tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild combination pills) worked as well as the existing formulation, but appears to have less potential for kidney and bone toxicity, according to a presentation Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]

Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least 2 active agents can reduce pill burden and side effects without compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

CROI 2013: CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-inflammatory Effects

Cenicriviroc, which blocks both CCR5 and CCR2 receptors on immune cells, is effective against HIV, better tolerated than current antiretrovirals, and has immunomodulatory activity that may reduce inflammation, according to a presentation yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more: